Use of pheromone compounds having MAP kinase modulating activity

A method of treating a warm-blooded animal afflicted with a disease selected from the group consisting of cancer, inflammation, neurodegenerative diseases, neurological diseases, autoimmune diseases, allergy related diseases and hormone related diseases, restenosis, psoriasis, myocardial infarction, wounds and tissue repair and conditions and symptoms thereof that would benefit from modulation of MAP kinase activity, comprising administering to the warm-blooded animal a MAP kinase modulating effective amount of a pheromone compound selected from the group consisting of cis-7-tetradecenal, cis-7-tetradecenol, cis-7-dodecenyl ester, heneicosene-11-one, cis-6-heneicosene-11 -one, cis4-tridecenyl ester, cis4-tridecen-1-yl ester, 2-heptanone, cis-7-tetradecenyl ester, trans-5-decenyl ester, cis-2-methyl-7-octadecene, cis-9-heneicosene, trans-2, cis-13-octadecadienal, 14-methyl-cis-8-hexadecenal, 2-methyl-3-butene-2-ol, trans-10-dodecenol, cis-9-tetradecenol, cis-9-tetradecenyl-formate, cis-9-tetradecenol, trans-3, cis-8, cis-11 -tetradecatrienol, cis-7-tridecenol, cis-9-pentadecenol, cis-9-undecenyl ester, trans-3, cis-7-tetradecadienyl ester, trans-3, cis-8-tetradecadienyl ester, and derivatives and analogs thereof.